DSP-5336

Phase 1Small molecule

Sumitomo Pharma America, Inc.

DSP-5336 is one of 5 small molecule programs targeting Blood Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood CancerNot yet recruiting

Blood CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Blood Cancer

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Phase 2

1 2

COVID-19 Vaccine

Moderna

Phase 2

1 3

Koselugo

AstraZeneca

Phase 1

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 5

DSP-5336

Sumitomo Pharma America, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blood Cancer1 trial

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Not yet recruiting· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT07444268·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DSP-5336. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DSP-5336 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DSP-5336. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sumitomo Pharma America, Inc.

DSP-5336

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blood Cancer1 trial

References

Drug Info

Quick Facts

Related News